Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRTX1133 in KRAS G12D+ Advanced Solid Tumors
NCT05737706Phase 1Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MRTX1133 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Number of Patients who Experience Dose-Limiting Toxicity at 21 Days, Number of patients who experience a treatment-related adverse event up to 2 years and 4 more. Started Mar 2023; status: terminated.
02
Drugs
MRTX1133
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05737706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737706.